Reduced lung cancer burden by selective immunomodulators elicits improvements in muscle proteolysis and strength in cachectic mice
Rattachement africain : es. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Identification of to what extent tumor burden influences muscle mass independently of specific treatments for cancer-cachexia remains to be elucidated. We hypothesized that reduced tumor burden by selective treatment of tumor with immunomodulators may exert beneficial effects on muscle wasting and function in mice. Body and muscle weight, grip strength, physical activity, muscle morphometry, apoptotic nuclei, troponin-I systemic levels, interleukin-6, proteolytic markers, and tyrosine release, and apoptosis markers were determined in diaphragm and gastrocnemius muscles of lung cancer (LP07 adenocarcinoma cells) mice (BALB/c) treated with monoclonal antibodies (mAbs), against immune check-points and pathways (CD-137, cytotoxic T-lymphocyte associated protein-4, programed cell death-1, and CD-19; N = 10/group). Nontreated lung cancer cachectic mice were the controls. T and B cell numbers and macrophages were counted in tumors of both mouse groups. Compared to nontreated cachectic mice, in the mAbs-treated animals, T cells increased, no differences in B cells or macrophages, the variables final body weight, body weight and grip strength gains significantly improved. In diaphragm and gastrocnemius of mAbs-treated cachectic mice, number of apoptotic nuclei, tyrosine release, proteolysis, and apoptosis markers significantly decreased compared to nontreated cachectic mice. Systemic levels of troponin-I significantly decreased in treated cachectic mice compared to nontreated animals. We conclude that reduced tumor burden as a result of selective treatment of the lung cancer cells with immunomodulators elicits per se beneficial effects on muscle mass loss through attenuation of several biological mechanisms that lead to increased protein breakdown and apoptosis, which translated into significant improvements in limb muscle strength but not in physical activity parameters.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Reduced lung cancer burden by selective immunomodulators elicits improvements in muscle proteolysis and strength in cachectic mice
- Date Crossref
- 09/03/2019
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Universitat Pompeu Fabra pays non établi dans la noticeUniversité ou école supérieure
-
Parc de Salut pays non établi dans la noticeÉtablissement de santé
-
Instituto de Salud Carlos III Centro de Investigación en Red de Enfermedades Respiratorias pays non établi dans la noticeOrganisme public
-
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias pays non établi dans la noticeStructure de recherche
-
Health and Experimental Sciences Department (CEXS) MIM‐Hospital del Mar Pulmonology Department‐Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer pays non établi dans la noticeÉtablissement de santé
-
MIM-Hospital del Mar Health and Experimental Sciences Department (CEXS) pays non établi dans la noticeÉtablissement de santé
Universitat Pompeu Fabra, Parc de Salut et Centro de Investigación en Red de Enfermedades Respiratorias — Instituto de Salud Carlos III, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.